title: [Endocrinal sequela in bone marrow transplantations during childhood and adolescence].
abstract: Bone marrow transplants are being increasingly used to treat a broadening spectrum of serious pediatric conditions including hematologic, metabolic, and immune disorders. A common adverse effect is slowing of statural growth which, according to the author's experience, reaches 0.4 SD a year on average in the highest risk group with progressive graft-versus-host disease after whole body irradiation and transplantation of an allograft. Growth was normal in autograft recipients treated by moderate-intensity chemotherapy. High-dose chemotherapy, in particular with busulfan and cyclophosphamide, has been reported to cause growth retardation. The mechanism of failure to gain height is complex. Partial growth hormone deficiency is rare. Relative resistance of growth plates is the most likely mechanism. The role and efficacy of growth hormone replacement therapy is unclear. Conditioning regimens can affect ovarian and testicular function. Peripheral thyroid resistance can occur after whole body irradiation and transplantation of an allograft. The high rate of growth and endocrine disorders warrants close monitoring including full evaluations of growth and pubertal development as well as periodic endocrinologic investigations.
authors.affiliation: Services de Médecine Infantile I, Hôpital d'Enfants, Centre Hospitalier Universitaire de Nancy. Vandoeuvre.
authors.forename: B
authors.initials: B
authors.lastname: Le Heup
authors.forename: A
authors.initials: A
authors.lastname: von Bueltzingloewen
authors.forename: P
authors.initials: P
authors.lastname: Bordigoni
authors.forename: D
authors.initials: D
authors.lastname: Sommelet
authors.forename: M
authors.initials: M
authors.lastname: Pierson
mesh_terms: D000293:Adolescent; D000367:Age Factors; D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000379:methods; D002066:Busulfan / Q000009:adverse effects; D002648:Child; D003131:Combined Modality Therapy; D016371:Cranial Irradiation / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D004700:Endocrine System Diseases / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D005260:Female; D006086:Graft vs Host Disease / Q000150:complications; D006130:Growth Disorders / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D013006:Growth Hormone / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010053:Ovary / Q000187:drug effects / Q000503:physiopathology / Q000528:radiation effects; D011627:Puberty; D012307:Risk Factors; D013737:Testis / Q000187:drug effects / Q000503:physiopathology / Q000528:radiation effects; D013961:Thyroid Gland / Q000187:drug effects / Q000503:physiopathology / Q000528:radiation effects; D014916:Whole-Body Irradiation / Q000009:adverse effects
chemical_list: D003520:Cyclophosphamide; D013006:Growth Hormone; D002066:Busulfan
vernacular_title: Séquelles endocriniennes des greffes de moelle osseuse pendant l'enfance et l'adolescence.